Menu
Search
|

Menu

Close
X

Intra-Cellular Therapies Inc ITCI.OQ (NASDAQ Stock Exchange Global Select Market)

15.38 USD
-0.48 (-3.03%)
As of 10:43 AM EST
chart
Previous Close 15.86
Open 15.85
Volume 15,093
3m Avg Volume 109,055
Today’s High 15.85
Today’s Low 15.21
52 Week High 25.74
52 Week Low 14.31
Shares Outstanding (mil) 54.73
Market Capitalization (mil) 947.31
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-2.091
FY17
-2.131
FY16
-2.693
FY15
-2.918
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.34
Price to Sales (TTM)
vs sector
187,216.00
20.58
Price to Book (MRQ)
vs sector
2.68
4.23
Price to Cash Flow (TTM)
vs sector
--
21.19
Total Debt to Equity (MRQ)
vs sector
0.00
13.84
LT Debt to Equity (MRQ)
vs sector
0.00
9.93
Return on Investment (TTM)
vs sector
-42.93
13.58
Return on Equity (TTM)
vs sector
-43.29
15.11

EXECUTIVE LEADERSHIP

Lawrence Hineline
Chief Financial Officer, Vice President - Finance, Treasurer, Assistant Secretary, Since 2014
Salary: $412,000.00
Bonus: $206,000.00
Mark Neumann
Executive Vice President, Chief Commercial Officer, Since 2018
Salary: --
Bonus: --
Andrew Satlin
Executive Vice President and Chief Medical Officer, Since 2017
Salary: $68,269.00
Bonus: $100,000.00
Robert Davis
Senior Vice President and Chief Scientific Officer, Since 2015
Salary: $412,000.00
Bonus: $222,500.00
Michael Halstead
Senior Vice President, General Counsel, Secretary, Since 2014
Salary: $455,300.00
Bonus: $227,700.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

430 E 29th St
NEW YORK   NY   10016-8367

Phone: +1212.9233344

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company's bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer's Disease (AD).

SPONSORED STORIES